A Phase II, Double-Blind, Randomized, Multi-Center, Adaptive Dose-Ranging, Placebo-Controlled, Parallel-Group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-Remitting Multiple Sclerosis. [FOR EXTENSION STUDY SEE 7000230025]

Trial Profile

A Phase II, Double-Blind, Randomized, Multi-Center, Adaptive Dose-Ranging, Placebo-Controlled, Parallel-Group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-Remitting Multiple Sclerosis. [FOR EXTENSION STUDY SEE 7000230025]

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2014

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms BOLD
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Oct 2012 Results assessing the correlation between magnetic resonance imaging and lymphocyte counts presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 13 Oct 2012 Primary analysis presented at the28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Apr 2012 Main efficacy results presented at the 64th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top